SULPHRIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sulphrin, and when can generic versions of Sulphrin launch?
Sulphrin is a drug marketed by Bausch And Lomb and is included in one NDA.
The generic ingredient in SULPHRIN is prednisolone acetate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SULPHRIN?
- What are the global sales for SULPHRIN?
- What is Average Wholesale Price for SULPHRIN?
Summary for SULPHRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 96 |
| DailyMed Link: | SULPHRIN at DailyMed |
US Patents and Regulatory Information for SULPHRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | SULPHRIN | prednisolone acetate; sulfacetamide sodium | SUSPENSION/DROPS;OPHTHALMIC | 088089-001 | Dec 28, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
